Circulating tumor cells: a window into cancer biology and metastasis

https://doi.org/10.1016/j.gde.2009.12.002Get rights and content

The presence of circulating tumor cells (CTCs) accompanies tumor invasion into the bloodstream. Detection, monitoring, and molecular analysis of these rare cancer cells shed into blood will provide a powerful and noninvasive approach for the detection of early disease, assessing prognosis and therapeutic response in established cancers, and targeting metastatic precursor cells. We review current and emerging technologies for CTC isolation, with a focus on capture efficiency, purity, and viability of CTCs, and their potential clinical applications.

Section snippets

References and recommended reading

Papers of particular interest, published within the period of review, have been highlighted as:

  • • of special interest

  • •• of outstanding interest

References (17)

There are more references available in the full text version of this article.

Cited by (271)

  • Developmental genes: the bridge between development and cancer metastasis

    2022, Unraveling the Complexities of Metastasis: Transition from a Segmented View to a Conceptual Continuum
  • Circulating tumor cell detection methods in renal cell carcinoma: A systematic review

    2021, Critical Reviews in Oncology/Hematology
    Citation Excerpt :

    These are extremely rare compared to whole blood cells, with an estimated CTCn of one CTC per billion normal blood cells in metastatic cancer patients.( Maheswaran and Haber, 2010) Additionally, a proportion of these cells is lost during sample processing, making their detection difficult and utterly reliant on the sensitivity and specificity of the methods used.( Bankó et al., 2019) Furthermore, the lack of specific RCC molecular markers has hindered CTC research in this tumor compared to other epithelial tumors.(

  • The value of circulating tumor cells with positive centromere probe 8 in the diagnosis of small pulmonary nodules

    2021, Translational Oncology
    Citation Excerpt :

    These CTCs are also recognized as an acceptable non-invasive tool for early cancer diagnosis, evaluation, and progression. The study of CTCs began more than a hundred year ago; however, advancements in the development and use of CTCs for diagnosis or prognosis have only emerged in recent years [11,12]. Currently, CellSearchⓇ is the only method approved by the US Food and Drug Administration (FDA) for clinical determination of CTCs, although various methods and technologies are used in academic studies and clinical diagnosis [13].

View all citing articles on Scopus
View full text